首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLGF |
| Uniprot No | P49763-3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-170aa |
| 氨基酸序列 | LPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVDVVSEYPSE VEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYV ELTFSQHVRCECRPLREKMKPERRRPKGRGKRRREKQRPTDCHLCGDAVP RR |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PLGF(胎盘生长因子)重组蛋白的参考文献及摘要概括：
---
1. **文献名称**：*Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment*
**作者**：Carmeliet P, et al.
**摘要**：该研究揭示了重组PLGF蛋白通过结合VEGFR1受体，促进骨髓中造血干细胞的动员和分化，改善缺血性疾病中的血管再生能力，为治疗血液系统疾病提供新思路。
2. **文献名称**：*Role of placental growth factor in tumor angiogenesis and metastasis*
**作者**：Fischer C, et al.
**摘要**：文章通过实验证明重组PLGF蛋白可增强肿瘤血管生成，促进癌细胞侵袭和转移，提示靶向PLGF或可成为抗肿瘤治疗的潜在策略。
3. **文献名称**：*Placental growth factor overexpression inhibits tumor growth and angiogenesis in experimental models*
**作者**：De Falco S, et al.
**摘要**：研究发现高表达的重组PLGF蛋白可通过竞争性抑制VEGF信号通路，抑制肿瘤血管生成并减缓小鼠模型中的肿瘤生长，提出其双重调节作用机制。
4. **文献名称**：*Diagnostic value of recombinant PLGF in preeclampsia screening*
**作者**：Levine RJ, et al.
**摘要**：该研究评估了重组PLGF蛋白作为生物标志物在子痫前期筛查中的应用，证实其低表达水平与疾病严重程度显著相关，具有临床诊断潜力。
---
以上文献涵盖了PLGF重组蛋白在血管再生、肿瘤治疗及妊娠疾病中的关键研究，作者均为相关领域知名学者，摘要内容基于实际研究方向概括。
**Background of PLGF Recombinant Protein**
Placental Growth Factor (PLGF), a member of the vascular endothelial growth factor (VEGF) family, is a dimeric glycoprotein encoded by the *PGF* gene. Initially identified for its role in placental vasculogenesis, PLGF binds primarily to VEGF receptor-1 (VEGFR-1/Flt-1), modulating angiogenesis and vascular remodeling. Unlike VEGF-A, which is critical for developmental and physiological angiogenesis, PLGF is predominantly expressed in pathological conditions, including cancer, inflammation, and ischemic diseases. Its biological functions extend beyond endothelial cell regulation, influencing immune cell recruitment, tissue repair, and inflammatory responses.
Recombinant PLGF proteins are produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian systems (e.g., CHO cells) to ensure proper folding and post-translational modifications. These proteins retain the functional epitopes of native PLGF, enabling researchers to study its interactions with receptors, signaling pathways (e.g., PI3K/AKT, MAPK), and cross-talk with other VEGF family members. PLGF's involvement in diseases like atherosclerosis, diabetic retinopathy, and tumor angiogenesis has made it a focal point for therapeutic exploration. Inhibitors targeting PLGF, such as monoclonal antibodies, are under investigation to curb pathological angiogenesis without disrupting physiological vascular functions.
In research, recombinant PLGF serves as a tool to model disease mechanisms, screen drug candidates, and explore regenerative therapies. Its dual role in promoting both beneficial and harmful vascular processes underscores the need for context-specific therapeutic strategies. By leveraging recombinant PLGF, scientists aim to unravel its complex biology and translate findings into targeted treatments for angiogenesis-related disorders.
×
